<DOC>
	<DOCNO>NCT01849042</DOCNO>
	<brief_summary>This study evaluate pharmacological efficacy language capability compliance combination new Ebixa oral pump donepezil compare donepezil patient probable Alzheimer 's disease . Primary objective evaluate efficacy memantine language capability moderate severe Alzheimer 's disease patient take stable donepezil treatment.Secondary objective evaluate efficacy maintain cognitive function disease progression K-MMSE , NPI , ROSA , SIB-short form probable AD .</brief_summary>
	<brief_title>Effect Memantine Oral Pump Language Patients With Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>probable Alzheimer 's disease accordance NINCDSADRDA criterion MMSE score equal less 20 Brain CT MRI scan perform within past 12 month live regular visit least three time week caregiver able visit outpatient clinic perform cognitive function test already take stable dose donepezil 3 month prior screen subject caregiver sign informed consent involve another clinical trial within 4 week prior screen severe unstable disease : acute severe asthma , unstable severe cardiovascular disease , acute peptic ulcer , chronic renal failure bradycardia ( pulse rate le 50bpm ) , sick sinus syndrome laboratory find include cognitive impairment ( vitamine B12 folic acid , syphilis , thyroid disease ) severe auditory visual disturbance degenerative disease psychosis take drug use treatment Alzheimer 's disease dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>